Pharmaceutical compositions, and methods of use thereof, for treating cerebral cavernous malformations and symptoms associated therewith. The pharmaceutical compositions include a therapeutically effective amount of a thrombospondin 1 protein agent. A thrombospondin 1 protein agent can include thrombospondin 1 protein, a functional fragment of thrombospondin 1 protein, an isomer, a homolog, or a peptidomimetic of thrombospondin 1 protein or a functional fragment thereof. The pharmaceutical compositions and methods can further comprise a Rho Kinase inhibitor.
展开▼
